Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 3/20 | 0.38 |
| ▸ | CASP3 | P42574 | 3/20 | 0.38 |
| ▸ | CASP9 | P55211 | 3/20 | 0.38 |
| ▸ | CYCS | P99999 | 3/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 10/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3709359 | 0.97 | APAF1 (0.36) | APAF1CASP3CASP9CYCSGPBAR1 | |
| SCHEMBL3705123 | 0.96 | GPBAR1 (0.37) | APAF1CASP3CASP9CYCSGPBAR1 | |
| SCHEMBL3704033 | 0.94 | APAF1 (0.36) | APAF1CASP3CASP9CYCSALDH1A1 | |
| SCHEMBL3702398 | 0.94 | APAF1 (0.35) | APAF1CASP3CASP9CYCSGPBAR1 | |
| SCHEMBL3695657 | 0.93 | GLA (0.40) | APAF1CASP3CASP9CYCSLMNA | |
| SCHEMBL3698185 | 0.89 | MAPT (0.36) | APAF1CASP3CASP9CYCSGPBAR1 | |
| SCHEMBL3700997 | 0.88 | APAF1 (0.38) | APAF1CASP3CASP9CYCSLMNA | |
| SCHEMBL3698076 | 0.88 | GPBAR1 (0.39) | GPBAR1USP2HTTTP53ALDH1A1 | |
| SCHEMBL3705051 | 0.87 | APAF1 (0.36) | APAF1CASP3CASP9CYCSUSP2 | |
| SCHEMBL3701736 | 0.87 | PSEN1 (0.37) | APAF1CASP3CASP9CYCSUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040701-B2 | Apaf-1 inhibitor compounds | LABORATORIOS SALVAT, S.A. (ES) | 2015-05-26 | — | — | US | disclosed |
| US-20120122868-A1 | APAF-1 INHIBITOR COMPOUNDS | LABORATORIOS SALVAT, S.A. (ES) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122868-A1 | APAF-1 INHIBITOR COMPOUNDS | APAF1, API5, AIFM1 | APAF1 1/4885CASP3 13/4885CASP9 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.